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In our clinical trials of oncolytic vesicular stomatitis virus expressing interferon beta
(VSV-IFNβ), several patients achieved initial responses followed by aggressive relapse. We
show here that VSV-IFNβ-escape tumors predictably express a point-mutated CSDE1P5S form
of the RNA-binding Cold Shock Domain-containing E1 protein, which promotes escape as an
inhibitor of VSV replication by disrupting viral transcription. Given time, VSV-IFNβ evolves a
compensatory mutation in the P/M Inter-Genic Region which rescues replication in CSDE1P5S
cells. These data show that CSDE1 is a major cellular co-factor for VSV replication. However,
CSDE1P5S also generates a neo-epitope recognized by non-tolerized T cells. We exploit this
predictable neo-antigenesis to drive, and trap, tumors into an escape phenotype, which can
be ambushed by vaccination against CSDE1P5S, preventing tumor escape. Combining frontline
therapy with escape-targeting immunotherapy will be applicable across multiple therapies
which drive tumor mutation/evolution and simultaneously generate novel, targetable
immunopeptidomes associated with acquired treatment resistance.
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Escape from frontline therapy is a major cause of treatmentfailure in cancer patients1–4, wherein a subset of patientsinitially develop promising clinical responses, followed
by aggressive, lethal, tumor growth. Hence, strategies that
reduce treatment failure through tumor escape would be highly
significant.
We have shown that treatment-escaped tumors differ sig-
nificantly from primary tumors immunogenically, genetically, and
phenotypically1–12, due to mutational plasticity and selection of
treatment-resistant clones1–4,9–11. These treatment-escape pheno-
types arise, at least in part, through the evolution of a pool of
mutated tumor cells from which highly aggressive, treatment-
resistant clones are rapidly selected1–4,9–11. In this respect, APO-
BEC (apolipoprotein B mRNA editing enzyme, catalytic polypep-
tide-like) cytosine deaminases provide an endogenous source of
DNA mutation-driving cancer evolution in response to a variety of
different frontline treatments1,9–11,13–20. APOBEC3 cytosine dea-
minases act as innate antiviral restriction factors and catalyze
cytosine to uracil deamination of ssDNA (C–T transitions and C–G
transversions)1,16,17. Although the human genome encodes seven
APOBEC3 enzymes (3A–H), the mouse encodes a single gene,
mAPOBEC31,17,21, which has similar activities to those of human
APOBEC3B (hAPOBEC3B)10. Consistent with APOBECs as dri-
vers of tumor escape, the APOBEC3B signature is associated with
therapeutic resistance in multiple cancers1,14,15,18–20.
We have shown that APOBEC3 induction following frontline
treatment with adoptive T-cell therapy, chemotherapy, or onco-
lytic virotherapy has profound consequences for the generation of
escape variants from all three types of therapy9–11. With respect
to oncolytic virotherapy, we, and others, have developed vesicular
stomatitis virus (VSV), a single-strand negative sense RNA virus
(Rhabdovirus, Indiana serotype), as an oncolytic platform for
clinical testing22–31. VSV, which is highly sensitive to inhibition
by interferon (IFN), shows selective replication in Type I IFN-
defective tumor cells, while being rapidly shut down in (IFN-
responsive) normal cells22–24. For the clinical development of
VSV32, we overexpressed the IFNβ gene in the virus25 to enhance
safety (increased antiviral IFN expressed in normal cells) and to
increase the immunogenicity of infected/dying tumor cells, as
IFNβ acts as a key signal 3 cytokine to facilitate priming of
tumor-reactive T cells25,32,33.
In our clinical trials of VSV-IFNβ as an oncolytic22–31, several
patients achieved initial responses followed by aggressive escape.
To understand the mechanistic basis of these effects, we estab-
lished in vitro and in vivo models in which suboptimal levels
of VSV infection leads to the escape of virus-resistant cells9,10.
We showed that suboptimal infection with VSV induced Type I
IFN-dependent hAPOBEC3B- or mAPOBEC3-induced mutation
of the cell genome, degradation of the viral genome, and escape of
virus/oncolysis-resistant (VSV-ESC) cells9,10. VSV-ESC cells10
carried stable APOBEC3B mutational signatures in multiple
genes11, some of which might be critical for escape. Simulta-
neously, we reasoned that some of these mutations may also
induce neo-antigenesis—the generation of neo-epitopes with
increased major histocompatibility complex (MHC) binding and
immunogenicity34–36, rendering VSV-ESC cells susceptible to T-
cell attack. Consistent with this hypothesis, we identified a C–T
mutation in the CSDE1 gene (CSDE1C-T) (proline to serine at
αα5, CSDE1P5S)11 in VSV-ESC cells10,11, which generated a
heteroclitic37–39 neo-epitope, which primed T-cell responses
against both itself (CSDE1P5S) and, to a lesser extent, wild-type
CSDE1[WT11. CSDE1, is multi-functional RNA-binding protein
that regulates RNA translation40–47.
We show here that CSDE1 is a critical mediator of
VSV replication, that the CSDE1P5S mutation facilitates
escape by inhibiting the oncolytic activity of the virus, and that
neo-antigenesis of CSDE1WT to CSDE1P5S generates an Escape-
Associated Tumor Antigen (EATA), which can be ambushed
by vaccination. Therefore, it is possible to combine frontline
virotherapy with escape-targeting immunotherapy, to target the
evolving immunopeptidome of treatment-resistant tumor cells.
Results
Escape from VSV-IFNβ oncolysis is associated with high-
frequency mutation in CSDE1. B16 populations, which we had
previously investigated as targets for virus-mediated treatment
escape (ESC) through APOBEC3 mutagenesis, selected for escape
from VSV-GFP (B16-VSV-GFP-ESC) were heterogeneous for
both CSDE1WT and CSDE1C-T (Supplementary Fig. 1A, B). B16-
HSVtk cells, which escaped ganciclovir chemotherapy9, had no
mutation in CSDE1 (Supplementary Fig. 1C). We had shown that
expression of IFNβ from the virus increased IFN, APOBEC3, and
the number of virus-resistant cells10. Whereas CSDE1C-T was
present at ~50% in B16-VSV-GFP-ESC cells, over 90% of CSDE1
sequence in B16-VSV-IFNβ-ESC cells was CSDE1C-T, suggesting
mutation at most of the alleles in ESC cells (Supplementary
Fig. 1D). However, when both B16-VSV-GFP-ESC and B16-
VSV-IFNβ-ESC cells were selected from B16 cells expressing
short hairpin RNA (shRNA) against mAPOBEC310, only
CSDE1WT was present (Supplementary Fig. 1E, F). CSDE1C-T was
present at >90% in murine and human VSV-IFNβ-ESC cells, and
always at a higher clonality than in VSV-GFP-ESC cells (Sup-
plementary Fig. 1G–I). CSDE1C-T was present in Mel888 tumors,
which escaped VSV-hIFNβ in vivo10, but only in ~30–50% of the
cells (Supplementary Fig. 1J), probably reflecting less efficient
in vivo infection.
Taken together, these data are consistent with the CSDE1C-T
mutation, which has a typical mAPOBEC3/APOBEC3B signature
(TTCA-TCCA)11,14,48, being induced through Type I IFN
induction of mAPOBEC3/hAPOBEC3B activity10,11 at a high
clonality in VSV-IFNβ ESC cells across species and tumor types
(Supplementary Fig. 1).
CSDE1 is a positive mediator of VSV replication and oncolysis.
These data suggested that CSDE1 may be critical for the
replication/oncolytic activity of VSV, that CSDE1C-T mutation
drives escape, and that co-expression of IFNβ enhances muta-
tion of this escape-promoting gene. Consistent with this,
replication of (Fig. 1A–C), and oncolysis by (Fig. 1D), VSV-
GFP was reduced by >2 orders of magnitude by CSDE1
knockdown in human cells46.
CSDE1C-T inhibits VSV replication. Similarly, VSV-IFNβ
replicated to significantly higher titers in B16 cells over-
expressing CSDE1WT (p < 0.0001 at 72 h) (Fig. 1E), but sig-
nificantly worse in B16 cells overexpressing CSDE1C-T (p < 0.0001
at 72 h), compared to parental B16 (Fig. 1E). B16-CSDE1C-T cells
still have both normal alleles of CSDE1 in situ and express
endogenous CSDE1WT, showing that CSDE1P5S could still exert a
strong selective pressure on the viral genome, across species and
histological types. Multiple passage of VSV-IFNβ through human
Hep3B-CSDE1WT (as a model of human hepatocellular cancer
cells against which we are testing VSV-IFNβ in clinical trials)
increased replication compared to passage through Hep3BP
parental cells (Fig. 1F). In contrast, after just a single passage
through Hep3B-CSDE1C-T cells, titers were significantly lower
than with passage through Hep3BP (p < 0.0001) (Fig. 1F). By
passage 3 through Hep3B-CSDE1C-T, titers began to recover and
reached almost Hep3BP levels by P5 (Fig.1F). Virus recovered
from five passages through Hep3BP (from Fig. 1F), replicated well
on Hep3BP cells (Fig. 1G), but had orders-of-magnitude lower
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titers on Hep3B-CSDE1C-T cells (Fig. 1G). Conversely, virus from
five passages through Hep3B-CSDE1C-T replicated poorly on
Hep3BP cells but at near-wild-type levels on Hep3B-CSDE1C-T
cells (Fig. 1G). Thus, VSV-IFNβ can, if given sufficient time,
adapt to the emergence of escape cells by complementing the
CSDE1C-T mutation.
VSV can be forced to evolve to adapt to the CSDE1C-T muta-
tion. VSV-IFNβ recovered from five passages through Hep3B-
CSDE1C-T cells [high titer on Hep3B-CSDE1C-T cells, low titer on
Hep3BP (Fig. 1G)] consisted of a population of quasi-species of
viruses, which contained a single C–U mutation in the intergenic
region (IGR) between the P and M genes (Fig. 2A) at high fre-
quency in the whole population (Fig. 2B, C). This IGR P/MC-U
mutation was undetectable in the stock VSV-IFNβ or in VSV-
IFNβ recovered from five passages through Hep3BP (Fig. 2A–C).
The same IGR P/MC-U mutation was recovered from VSV-IFNβ
serially passaged 5× through Mel888-CSDE1C-T melanoma cells.
Similarly, VSV-IFNβ recovered from five passages through
Hep3B cells, which had previously been selected for resistance to
VSV-IFNβ over 21 days (Hep3B-VSV-hIFNβ ESC), or through
Mel888-21d-VSV-hIFNβ ESC cells, was almost entirely mutant
for the IGR P/MC-U mutation (Fig. 2D). Finally, virus recovered
from a Hep3B escape tumor following treatment with VSV-
hIFNβ contained a mixed population of wild-type IGR P/M and
mutant IGR P/MC-U viruses (Fig. 2E).
CSDE1 regulates levels of viral P and M mRNA. CSDE1, an
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Fig. 1 CSDE1 is a positive modulator of VSV replication. A Hep3B cells were transfected with no siRNA, Negative control siRNA, or with [s15373+
15374 siRNA] (2 CSDE1-specific siRNA)46 and levels of CSDE1 assayed by western blotting 24 or 48 h later. (Representative of three separate
experiments). B–D Forty-eight hours following transfection with siRNA as in A, Hep3B cells were infected with VSV-GFP (MOI 0.1). Forty-eight hours
(B) or 96 h (C) later, viral titers were determined by plaque assay and D the number of surviving cells was counted at 96 h post infection. Representative of
two separate experiments. E B16-, B16-CSDE1C-T-, or B16-CSDE1WT-overexpressing cells were infected with VSV-IFN-β at an MOI of 0.1. Twenty-four, 48,
and 72 h later, viral titers were measured on BHK cells by plaque assay. Representative of three separate experiments. F Parental Hep3B cells or pooled
populations of Hep3B-overexpressing wild-type CSDE1WT, or mutant CSDE1C-T, were infected with VSV-IFN-β (MOI 0.1) (3 wells/group). Forty-eight
hours later (Passage 1), supernatants were assayed for infectious titers on the same cells on which the virus was passaged. Virus was recovered every 48 h
(P2–5) and similarly titered. Representative of three separate experiments. G Stock VSV-IFN-β virus or VSV-IFN-β, which had been passaged five times
through Hep3B parental or Hep3B-CSDE1C-T cells as in F, was titered on either Hep3B parental cells or on Hep3B-CSDE1C-T cells. Representative of two
separate experiments. Means ± SD of three technical replicates are shown. P-values were determined using a one-way (B–D) or two-way (E–G) ANOVA
with a Tukey’s multiple comparisons post test on log-transformed data. Statistical significance was set at p < 0.05, ns > 0.05. Source data are provided as a
Source Data file.
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binds RNA at a consensus site of 5′-(purine)(aagua)-3′47.
The IGR P/MC-U point mutation C–U on the negative sense
strand of the VSV genome corresponds to a G–A mutation on
the positive sense strand (Fig. 2A) precisely within an
exact copy of the consensus CSDE1-binding site in the IGR
between the P and M genes47 (Fig. 2A) (5′-aaaaa(aaGua)-3′
to 5′-aaaaa(aaAua)-3′). This consensus site will only be present
in viral positive sense transcripts when the positive sense
genomic full-length strand is made during normal replication
of the VSV genome (negative to positive RNA). Alternatively,
it will exist if a sub-genomic, positive strand P–M mRNA
is made when the polymerase reads through the P/M IGR to
make a unicistronic P–M mRNA. Such readthrough is rare,
because P and M mRNAs are usually made by disengagement of
Fig. 2 Forced evolution of VSV selects a single point mutation in the P/M IGR. VSV-IFNβ was passaged 5× through Hep3B or Hep3B-CSDE1C-T cells as in
Fig. 1. Sanger sequence of the IGR between the P and M genes (A) from virus populations passaged through B Hep3B parental cells showed homogenous
populations of wild-type sequence; sequence of viruses passaged through either C Hep3B-CSDE1C-T cells or D Hep3B-VSV-IFNβ−21d ESC cells were
largely homogenous for a point mutation C–U. Representative of five separate experiments. E Virus population from a Hep3B tumor grown in a SCID mouse
and excised upon recurrence following treatment with VSV-IFNβ was a heterogenous population of wild-type and mutant IGR P/M viruses. Representative
of two separate escape tumors.
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polymerase at the P–M IGR followed by re-initiation at the
M gene.
Therefore, we measured P, M, and P–M mRNAs transcribed
from VSV-IFNβ or VSV-IFNβ-IGR P/MC-U, upon infection
of B16 and Hep3BP, or B16-CSDE1C-T and Hep3B-CSDE1C-T,
cells within 6 h of infection, which represents an early stage of
replication (Fig. 3). When levels of RNA were normalized to those
observed in cells infected by the wild-type VSV-IFNβ, there were
no significant changes in levels of P RNA in both B16 and Hep3B
cells infected with VSV-IFNβ-IGR P/MC-U (Fig. 3A). In both
Hep3B and B16 cells overexpressing CSDE1P5S, levels of P RNA
were slightly decreased compared to VSV-IFNβ (Fig. 3A). However,
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infection of both cell types overexpressing CSDE1P5S with VSV-
IFNβ-IGR P/MC-U completely normalized levels of P RNA. In
contrast to moderate, or no, changes in the levels of P RNA, levels
of M RNA were significantly decreased following infection of
Hep3B-CSDE1C-T cells with VSV-IFNβ, or upon infection of
Hep3BP cells with VSV-IFNβ-IGR P/MC-U (Fig. 3B). As for the
levels of P RNA, infection of Hep3B-CSDE1C-T with VSV-IFNβ-
IGR P/MC-U completely normalized the levels of M RNA and
protein, showing that the negative effects of CSDE1P5S on
transcription of viral M RNA were compensated by the presence
of the IGR P/MC-U mutation in the viral genome (Fig. 3B). The
same effects were replicated in B16 cells (Fig. 3B).
At this early stage of viral replication time point, relative to
VSV-IFNβ infection of parental cell types, the levels of P–M
bicistronic RNA were increased between 20- and 30-fold upon
infection of Hep3B, or B16, cells with VSV-IFNβ-IGR P/MC-U,
and between 10- and 30-fold in both Hep3B and B16 cells
overexpressing CSDE1P5S infected with VSV-IFNβ (Fig. 3C).
Once again, infection of CSDE1P5S-overexpressing cells with the
complementing IGR P/MC-U compensatory mutation in VSV-
IFNβ-IGR P/MC-U was sufficient to normalize the levels of P–M
RNA to those levels seen in wild-type infection (Fig. 3C).
In contrast to the loss of RNA for the viral M protein, coupled
with significantly increased levels of P–M RNA (Fig. 3B), relative
levels of viral G and L RNA, as well as G–L RNA, were not
significantly changed in Hep3B, or in B16, cells infected with
VSV-IFNβ-IGR P/MC-U, or in either cell line overexpressing
CSDE1P5S infected with VSV-IFNβ, compared to levels in
parental cells infected by VSV-IFN-β (Fig. 3D–F). These data
indicate that CSDE1 specifically affects mRNA synthesis
termination between P and M, and not at other IGRs of the
virus. This is consistent with the IGR between the P and M genes
of VSV having a unique sequence of 5′-aaaaa(aaGua)-3′—which
is a perfect CSDE1 consensus binding site. In contrast, all of the
remaining viral IGR (N/P, M/G, and G/L) have a similar, but
distinct, sequence of 5′-aaaaa(aaCua)-3′.
These quantitative reverse transcriptase PCR (qrtPCR) data
suggested that the CSDE1P5S protein interferes with early-stage
VSV replication (at 6 h), leading to significant loss of unicistronic
M RNA and relative increases of bicistronic P–M RNA. This
would predict that levels of viral M protein would be significantly
reduced in cells expressing mutated CSDE1P5S infected by VSV-
IFNβ or by cells expressing wild-type CSDE1 and infected by the
VSV-IFNβ-IGR P/MC-U virus. Consistent with this hypothesis,
and with the qrtPCR results (Fig. 3B), compared to Hep3B cells
infected with VSV-IFNβ (Fig. 3G, lane 2), infection with VSV-
IFNβ-IGR P/MC-U led to markedly reduced levels of M protein at
both 6 and 18 h post infection (lane 3). Overexpression of
CSDE1wt protein in the Hep3B cells could not rescue M protein
expression following infection with VSV-IFNβ-IGR P/MC-U (lane
4), although it maintained, and moderately increased, the levels of
M protein from infection with VSV-IFNβ (lanes 2 and 5).
Overexpression of the CSDE1P5S mutant protein was inhibitory
to replication of VSV-IFNβ as measured by the levels of M
protein (lanes 2 and 6) but rescued the expression of M protein
from the VSV-IFNβ-IGR P/MC-U virus (lane 8). In addition,
Hep3B cells, which had undergone stringent in vitro selection to
escape VSV-IFNβ oncolysis (Hep3B-VSV-IFNβ-ESC), and which
contain the CSDE1C-T mutation at very high frequency
(Supplementary Fig. 1), produced significantly less M protein
when infected with VSV-IFNβ compared to infection with VSV-
IFNβ–IGR P/MC-U (Fig. 3D, lanes 7 vs. 9).
VSV expressing an escape-associated tumor antigen. The
APOBEC3B-generated CSDE1C-T mutation creates a heteroclitic
neo-epitope in the B16/C57Bl/6 model11 and is selected for in
tumors forced to escape VSV-IFNβ. This treatment-driven neo-
antigenesis makes CSDE1P5S an EATA target for immunotherapy
against treatment-resistant tumors. Therefore, we constructed
viruses expressing either CSDE1WT or the CSDE1P5S EATA (Fig.
4A). Consistent with Fig.1, overexpression of CSDE1WT from
VSV significantly enhanced viral replication on human and
murine (but not hamster) cells, compared to VSV-GFP (Fig. 4B).
Conversely, viral-driven CSDE1P5S exerted a significant negative
effect (Fig. 4B). Low multiplicity of infection (MOI) infection of
Hep3BP or B16 cells with VSV-IFNβ-CSDE1WT significantly
reduced both escape (Fig. 4C) and the escape-enabling CSDE1C-T
mutation (~10–50% in Fig. 4D, compared to >90% in Supple-
mentary Fig. 1I) compared to VSV-IFNβ.
Trap and ambush immunotherapy for tumor escape. Mice
treated intratumorally (i.t.) with VSV-mIFNβ-CSDE1WT or
VSV-mIFNβ-CSDE1C-T (Fig. 5A) generated comparable strong
antiviral T-cell responses (Fig. 5B). Although VSV-mIFNβ-
CSDE1WT did not generate α-CSDE1WT T cells, VSV-mIFNβ-
CSDE1C-T induced potent T-cell responses against the CSDE1P5S
neoantigen (Fig. 5B) as well as weaker responses against B16-
CSDE1WT and B16 (expressing endogenous CSDE1), confirming
that CSDE1P5S acts as a heteroclitic neo-epitope in the C57Bl/6
model11. These T-cell responses probably contributed to the
significantly reduced tumor sizes in mice treated with VSV-
mIFNβ-CSDE1C-T compared to those treated with VSV-mIFNβ-
CSDE1WT at day 30 when this experiment was stopped (Fig. 5A).
Only VSV-mIFNβ-CSDE1C-T induced intra-tumoral interleukin
(IL)-12 after six i.t. injections (Fig. 5C), which correlated with the
anti-tumor T-cell response (Fig. 5B). All three viruses induced
similar levels of tumor necrosis factor-α (TNF-α) within injected
tumors (Fig. 5D).
Fig. 3 CSDE1 regulates viral M RNA levels. Cells (HepB3 or HepB3-CSDE1C-T; B16 or B16-CSDE1C-T) were infected with VSV viruses (VSV-IFNβ or VSV-
IFNβ-IGR P/MC-U) at an MOI of 3. Lanes: 1, Hep3B/VSV-hIFNβ; 2, Hep3B/VSV-hIFNβ-IGR P/MC-U; 3, Hep3B-CSDE1C-T/VSV-hIFNβ; 4, Hep3B-CSDE1C-T/
VSV-hIFNβ-IGR P/MC-U; 5, B16/VSV-mIFNβ; 6, B16/VSV-mIFNβ-IGR P/MC-U; 7, B16-CSDE1C-T/VSV-mIFNβ; and 8, B16-CSDE1C-T/ VSV-mIFNβ-IGR P/
MC-U. Six hours later, RNA was isolated and converted into cDNA. qrtPCR was used to assess levels of A viral P RNA (P-specific primers P1 and P2), B viral
M RNA (M-specific primers M1 and M2), or C viral P–M RNA (P/M IGR-M-specific primers IGR1 and M2). Representative of three separate experiments.
D–F Levels of G, L, and G–L RNA were measured as in A–C using primers G1 and 2, L1 and 2, and G1–L2, respectively. Representative of two separate
experiments. Levels of each RNA species were normalized to expression in Hep3B infected with VSV-hIFNβ or to B16 infected with VSV-mIFNβ. G Hep3B
parental cells (Hep3B) (Lanes 1–3) or Hep3B cells engineered to overexpress CSDE1wt (Hep3B-CSDE1wt) (lanes 4 and 5) or mutated CSDE1P5S (Hep3B-
CSDE1C-T) (lanes 6 and 8) proteins, or Hep3B that had been selected in vitro for resistance to VSV-IFNβ oncolysis for 21 days (Hep3B-VSV-IFNβ-ESC)
(lanes 7 and 9), were infected with wild-type VSV-IFNβ (lanes 2 and 5–7) or VSV-IFNβ-IGR P/MC-U (lanes 3, 4, 8, and 9) at an MOI of 3. Cells were
collected at either 6 or 18 h post infection and levels of viral M protein were measured by western blotting. Representative of two separate experiments
means ± SD of three biological replicates are shown (A–F). P-values were determined using a one-way ANOVA (A–F) on the raw data. Statistical
significance was set at p < 0.05, ns > 0.05. *p < 0.05, **p < 0.1, ***p < 0.001. Source data are provided as a Source Data file.
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Immune checkpoint blockade (ICB) with α-PD-1 antibody49–52
concomitant with i.t. virus, significantly decreased IL-12 in VSV-
mIFNβ-CSDE1C-T-treated tumors (Fig. 5C). In contrast, αPD-
1 ICB 4 days after the first viral injection significantly increased
IL-12 in VSV-mIFNβ-CSDE1C-T-treated tumors (Fig. 5C). Levels
of TNF-α were not significantly altered from no, or early, ICB
(Fig. 5D).
To compare the relative therapeutic contributions of increased
viral replication/oncolysis (VSV-mIFNβ-CSDE1WT) with
decreased oncolysis but treatment-driven neo-antigenesis in
VSV-IFNβ-ESC tumors (VSV-mIFNβ-CSDE1C-T), mice were
treated i.t. with viruses+ α-PD-1 late after induction of T-cell
responses (Fig. 5E). VSV-mIFNβ prolonged survival compared to
phosphate-buffered saline (PBS), but all tumors eventually
escaped (Fig. 5F). VSV-IFNβ-CSDE1WT significantly increased
median survival compared to VSV-mIFNβ (Fig. 3F), correlated
with enhanced i.t. replication (Fig. 5G) (consistent with Fig. 4).
However, expression of the CSDE1P5S EATA from the virus
completely prevented tumor escape (Fig. 5F), despite significantly
less replication in tumors compared to either VSV-mIFNβ or
VSV-mIFNβ-CSDE1WT (Figs. 5G and 4). It is unlikely that
evolution of the escape-promoting CSDE1P5S mutation occurs in
100% of all cells in the ESC tumors (e.g., see Supplementary
Fig. 1J). Therefore, our model of tumor clearance depends upon
the heteroclitic anti-CSDE1P5S/anti-CSDE1WT T-cell response
being potent enough to clear that proportion of tumor cells in
which the CSDE1P5S mutation had not evolved following VSV-
IFNβ therapy. In this respect, as we have seen previously,
adoptive transfer of in vitro-activated OT-I CD8+ T cells
(specific for the irrelevant SIINFEKL epitope of Ovalbumin) in
combination with anti-PD-1 ICB had no significant therapeutic
effect upon the growth of subcutaneous B16 tumors (100%
CSDE1WT) (Supplementary Fig. 3A). In contrast, CD8+ T cells
recovered from mice that had survived B16 tumors treated with
VSV-CSDE1P5S (Fig. 5F) and expanded in vitro against the
mutated CSDE1P5S MFSDSNLLH peptide, significantly extended
survival compared to the control-treated group, and cured a
proportion of mice (Supplementary Fig. 3A). Addition of ICB
with anti-PD-1 antibody significantly further enhanced the
efficacy of the adoptive transfer of anti-CSDE1P5S CD8+
T cells and cured 100% of mice (Supplementary Fig. 3A). Finally,
adoptive transfer of anti-CSDE1P5S CD8+ T cells in combination
with frontline treatment with VSV-IFNβ also cured all the mice
(even in the absence of ICB), whereas a combination of VSV-
IFNβ and OT-1 CD8+ T cells was no more effective than the
virus alone (Supplementary Fig. 3B). These data show that T cells
raised against mutant CSDE1P5S are therapeutically sufficient to
treat tumors expressing CSDE1WT antigen, despite the weaker
strength of the heteroclitic response against B16 cells compared to
that against B16-CSDE1P5S-expressing ESC cells.
Dendritic cell vaccination against an escape-associated tumor
antigen. To separate the conflicting effects of decreased
oncolysis (Figs. 4 and 5G) against neo-antigenesis (Fig. 5F), we
tested EATA-targeted immunotherapy using dendritic cells (DC)
Fig. 4 CSDE1 expressed from the virus enhances replication. A Viruses expressing CSDE1WT and CSDE1C-T were constructed and validated by western
blotting for the expression of CSDE1. Stars indicate clones that were used in subsequent experiments. Representative of three separate experiments. B BHK
(hamster), B16 (mouse), Hep3B, and Mel888 (human) cell lines were infected with VSV-GFP, VSV-hIFN-β, VSV-CSDE1WT, or VSV-CSDE1C-T at an MOI of
3 (triplicate wells per cell line). Forty-eight hours later, virus was titered on BHK cell by plaque assay. Representative of three separate experiments.
C Murine B16 or human Hep3B cells were infected (MOI 0.01) with VSV-IFNβ, VSV-IFN-β-CSDE1WT, or with VSV-IFN-β-CSDE1C-T viruses (using species-
matched IFNβ genes) for 21d as in “Methods” and ref. 10. Surviving cells were pooled and counted. D Hep3B cells were infected (MOI 0.01) with the VSV-
hIFNβ-CSDE1WT virus for 21d as in “Methods” and ref. 10. Surviving cells were pooled and genomic DNA prepared. Sanger sequencing of CSDE1 is shown
for two independent experiments. In these experiments, as well as in two other experiments, a mixed population of mutated and unmutated cells were
selected. Means ± SD of three technical replicates are shown. P-values were determined using a two-way (B) or one-way (C) ANOVA with a Tukey’s
multiple comparisons post test on log-transformed data. Statistical significance was set at p < 0.05, ns > 0.05. Source data are provided as a Source
Data file.
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expressing CSDE1P5S. DC-CSDE1C-T also generated strong α-
CSDE1P5S T-cell responses (Supplementary Fig. 2A, B). VSV-
IFNβ+DC-CSDEC-T+ α-PD-1 significantly enhanced therapy
relative to VSV-IFNβ+DC-CSDEWT+ α-PD-1 (Supplementary
Fig. 2C), but never achieved the 100% cure rates of VSV-IFNβ-
CSDE1C-T+ α-PD-1 (Fig. 5F), which correlated with ~3-fold
lower levels of i.t. IL-12 (Supplementary Fig. 2D and Fig. 5C).
Human tumor cells that escape VSV-IFNβ are immunogenic.
We investigated whether CSDE1P5S, and other undefined
EATA, would be immunogenic for human T cells. In three
separate co-cultures, CD3/CD28-activated human CD3+ T cells
had different baseline reactivity against Hep3B targets, reflecting
different alloreactivities11,53–55 (Fig. 6A, B). Nonetheless, both
APOBEC3B-mutated Hep3B targets and CSDE1C-T-expressing
Hep3B-VSV-hIFNβ-ESC cells (Supplementary Fig. 1I) were sig-
nificantly more immunogenic than Hep3BP across all three
donors (Fig. 6B). Immunogenicity was significantly reduced by
knockdown of CSDE146 (Fig. 6B), suggesting that neo-antigenesis
of hCSDE1P5S may serve as an EATA. T cells expanded against
Hep3B were unable to kill either Hep3B or Hep3B-VSV-IFNβ-
ESC targets (Fig. 6C). In contrast, T cells expanded against
Hep3B-VSV-IFNβ-ESC cells showed significant cytotoxicity
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cytotoxicity against Hep3B, suggesting that some T-cell responses
against EATA may be heteroclitic. Of all possible 8-, 9-, 10-, and
11-mers with the Proline–Serine mutation at amino acid 5, the
9mer, MSFDSNLLH, was predicted to have weak binding affinity
for human leukocyte antigen- (HLA) A*01:01, HLA-A*03:01,
and HLA-B*58:01 (Fig. 6D), which, for HLA-A*01:01 and HLA-
B*58:01, was predicted to be stronger than the wild-type epitope
MSFDPNLLH. T cells from one additional donor could be
primed by CSDE1C-T-transfected DC, but not by CSDE1WT-
transfected DC, to recognize the CSDE1P5S EATA. However,
T cells from a second donor did not recognize either wild-type or
mutated CSDE1 (Fig. 6E). Both donors 4 and 5 showed high level
T-cell priming against Hep3B-VSV-IFNβ-ESC cells compared to
Hep3B (Fig. 6E), as with Fig. 6B. Thus, escape from VSV-hIFNβ
generated cells that were consistently more immunogenic than
parental in both human and murine contexts.
CD3+ T cells from one of three additional donors secreted
significantly more IFN-γ when stimulated in vitro with DC-
presented, mutated CSDE1P5S 9mer peptide (MSFDSNLLH)
compared to either the DC-presented wild-type CSDE1 9mer
(MSFDPNLLH) or the negative control SIINFEKL peptide (Fig.
6F). However, CD3+ T cells from all three donors secreted
significantly more IFN-γ when stimulated in vitro with a 20mer
peptide in which the Pro-Ser mutation in CSDE1P5S could
potentially be presented by DC at any position in a loaded HLA
molecule, compared to when DC were loaded with the wild-type
20mer or the SIINFEKL peptide (Fig. 6F). These data provide
additional support for the hypothesis that neo-antigenesis of
hCSDE1P5S serves as an EATA.
Discussion
Here we exploited neo-antigenesis resulting from high mutational
plasticity of tumors, which also facilitates treatment escape, to
impose a powerful immunotherapy against escape tumors as they
are forced to evolve in response to frontline treatment. By targeting
a predictable and reproducible mutation induced with high clon-
ality within treatment-escape tumors, we were able to improve the
efficacy of VSV-IFNβ viro-immunotherapy significantly over that
obtained with the virotherapy alone.
Escape from treatments such as oncolytic virotherapy can
occur for multiple reasons1–4, involving not only tumor cell
mutational plasticity but also other mechanisms including a
simple lack of efficient infection, HLA incompatibility with
EATA, immune suppression, and antiviral tumor microenviron-
ments. However, we show that mutational pathways, such as
APOBEC3B, induced by frontline treatment with our clinical
agent VSV-IFNβ lead to the emergence of escape variants
carrying a very specific mutation, which is heavily selected for at
high frequency (Supplementary Fig. 1). We reasoned that such
mutations may be in genes/proteins that mediate escape from
innate and adaptive immune-mediated mechanisms of tumor
clearance induced by VSV infection26–31, and/or may allow
infected cells to downregulate critical steps in viral replication and
thereby escape oncolysis.
CSDE1 is multi-functional RNA-binding protein that regulates
RNA translation40–47. CSDE1 has not previously been reported to
be involved in the regulation of VSV replication, although it has
been shown to stimulate cap-independent translation initiation
for several other viruses (reviewed in ref. 45). Thus, knockdown of
CSDE1 reduced the internal ribosome entry site (IRES)-driven
translation of both human rhinovirus (HRV) and poliovirus,
while not affecting cap-dependent translation56. In the case of
HRV-2, CSDE1 binding to viral mRNA alters its structure to
facilitate further binding of the polypyrimidine tract-binding
protein, creating a structure that is necessary for translational
competency57. Thus, CSDE1 can be viewed as an RNA chaper-
one, which facilitates the formation of tertiary protein/RNA
complexes, thereby bridging viral RNAs and proteins that cannot
bind directly to each other.
Across species and tumors, knockdown of CSDE1 significantly
decreased VSV replication, whereas its overexpression enhanced
virus replication (Figs. 1 and 4). Overexpression of CSDE1P5S also
significantly decreased VSV replication (Figs. 1 and 4), despite
intact endogenous CSDE1WT protein. Therefore, this point muta-
tion creates a mutant protein, which exerts a potent inhibitory effect
on VSV replication.
VSV forced to evolve on cells overexpressing CSDE1P5S initially
had very low titers, but adapted to recover its fitness after multiple
passages (Fig. 1), which correlated with the emergence of a com-
pensatory C–U mutation in the virus at the P/M IGR (Fig. 2). Thus,
if given sufficient time, VSV-IFNβ was able to adapt to treatment-
escape cells, although viral adaptation lagged behind tumor muta-
tion/evolution, thereby allowing treatment escape.
The data in Fig. 3 show that mutant CSDE1P5S acts at the P/M
IGR of wild-type VSV-IFNβ, leading to significant reductions in
levels of M mRNA and protein, as well as increased levels of
aberrant bicistronic P–M RNA. Virus carrying the IGR P/MC-U
mutation in the presence of only wild-type CSDE1WT generated
similarly aberrant levels of M mRNA and protein. However, the
combination of cellular CSDE1P5S protein and viral IGR P/MC-U
mutation act in a self-complimentary manner to normalize viral P
and M RNA levels for efficient viral replication. These data are
consistent with the presence of a predicted consensus binding
site for CSDE147 —5′-aaaaa(aaGua)-3′—on the positive sense
Fig. 5 Virotherapy trap and immunotherapy ambush. A C57Bl/6 mice bearing 10d B16 tumors were injected i.t. with PBS, VSV-mIFNβ, VSV-mIFNβ-
CSDE1WT, or VSV-mIFNβ-CSDE1C-T. At day 30, mice were killed for collecting splenocytes and tumor sizes were measured as shown. B Splenocytes
collected at d30 were re-stimulated with VSV-N-specific immunodominant peptide (N52-59), SIINFEKL peptide from OVA, or with B16 cells overexpressing
CSDE1WT or CSDE1C-T, or with B16 or B16ova cells (E : T 10 : 1) for 72 h. Supernatants were assayed for IFN-γ. Representative of two separate experiments.
C, D Mice were injected with viruses as in A with added groups (three mice per group), which received no immune checkpoint blockade (ICB), or αPD-1
antibody i.p. at days 10, 12, and 14 or at days 14, 17, and 21. Twenty-four hours after the last injection of virus (d22), or earlier if tumor > 1.0 cm diameter
(PBS groups), tumors were dissociated and assayed for C IL-12 or D TNF-α by ELISA (normalized by protein concentration in whole tumor lysates as pg/ml
protein). E C57Bl/6 mice with 10d B16 tumors were injected i.t. with PBS, VSV-mIFNβ, VSV-mIFNβ-CSDE1WT, or with VSV-mIFNβ-CSDE1C-T (107 pfu/
injection) followed by α-PD-1 (n= 8/group). F Kaplan–Meier survival for groups in E. P-values were determined using the log-rank Mantel–Cox test. For
multiple comparisons using the Bonferroni correction, overall statistical significance threshold was set at α= 0.05 (3 comparisons at p < 0.0125 (4
comparisons)). Representative of two separate experiments. G C57Bl/6 mice with 10d B16 tumors were injected i.t. with (column 1) PBS, (2) VSV-mIFNβ,
(3) VSV-mIFNβ-CSDE1WT, or (4) VSV-mIFNβ-CSDE1C-T (107 pfu/injection) on days 10, 11, and 12. On d13, tumors were excised and virus measured by
plaque assay on BHK cells. Representative of two separate experiments. Each symbol in B–D and G represents a mouse (n= 3/group). Means ± SD are
shown. ND, not detected (below limit of detection). P-values were determined using a two-way (B) or one-way ANOVA (C, D, and G) with a Tukey’s
multiple comparisons post test. Statistical testing was performed on log-transformed data in G. Statistical significance set at p < 0.05 for B–D and G. Source
data are provided as a Source Data file.
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genomic strand of the VSV genome in the IGR between the P and
M genes (Fig. 2A). Overall, these data suggest a model in which
CSDE1WT binding to the consensus binding site on the positive
sense strand at the P/M IGR facilitates viral polymerase disen-
gagement to make unicistronic P and M mRNAs. Mutated
CSDE1P5S may inhibit this disengagement, thereby significantly
deregulating viral transcription, leading to decreased unicistronic
M RNA (Fig. 3B), increased bicistronic P–M RNA (Fig. 3C), and
loss of M protein (Fig. 3G). In this scenario, the complementary
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CSDE1P5S to bind to the mutated consensus site and restore wild-
type relative levels of P, M, and P–M readthrough RNA. Our data
suggest that CSDE1 specifically affects mRNA synthesis termi-
nation between P and M, but not between other viral genes,
despite the IGR sequences of VSV being very similar. However,
the IGR sequence between P and M (5′-aaaaa(aaGua)-3′) differs
from all the other IGR by a single base. Thus, the IGR sequence
between N and P, M and G, and G and L is (5′-aaaaa(aaCua)-3′).
This C–G change, which is only present in the P/M IGR, converts
the sequence (5′-aaaaa(aaCua)-3′) into a perfect CSDE1 con-
sensus binding site (5′-aaaaa(aaGua)-3′). Therefore, we hypo-
thesize that CSDE1 specifically affects mRNA synthesis
termination between P and M, and not at other very similar IGRs
of the virus, because the P/M IGR is the only site with the perfect
CSDE1 consensus binding site. Experiments are underway to
determine whether CSDE1 binds only at the perfect CSDE1 site in
the P/M IGR (and not at all at the other viral IGRs) or whether
there are different levels of CSDE1 binding throughout the
viral IGRs.
Taken together, these data show (i) that CSDE1 is a major
positive regulator of VSV replication; (ii) that CSDE1P5S acts as
an inhibitor of VSV replication facilitating escape from viral
oncolysis; (iii) and that, although tumor cells readily evolve to
escape viral therapy (CSDE1WT to CSDE1P5S), the oncolytic virus
can, if given sufficient time, also itself evolve to complement those
mutations that occur in its replication substrate.
Consistent with this model, CSDE1 expressed from VSV (VSV-
IFNβ-CSDE1WT) enhanced replication in vitro and in vivo (Figs.
4B and 5G), reduced escape (Fig. 4C), inhibited evolution of the
escape-promoting CSDE1C-T mutation (Fig. 4D), and was sig-
nificantly more effective than our current clinical agent VSV-
IFNβ (Fig. 5E, F). These results support the development of VSV-
IFNβ-CSDE1 as a novel, improved clinical candidate beyond
VSV-IFNβ.
We developed VSV expressing IFNβ to increase antiviral safety
and anti-tumor immunogenicity25,32. However, addition of IFNβ
unexpectedly increased escape through increased APOBEC3B10,
resulting in enhanced clonality of CSDE1C-T compared to VSV-
GFP-ESC cells (Supplementary Fig. 1). Although this was an
unexpected byproduct of inclusion of IFNβ into the virus,
expression of the selected CSDE1C-T mutation in escape cells
presented an opportunity, which we sought to exploit through
targeting of this escape-induced mutation. Thus, as CSDE1C-T
encodes a heteroclitic neo-epitope in the C57Bl/6 model11
(Fig. 5B), we reasoned that, by forcing evolution of tumors to
express CSDE1C-T through virotherapy (neo-antigenesis), escape
variants could be ambushed by T-cell responses against this
predictable CSDE1P5S EATA. As VSV is an excellent platform for
vaccination against tumor antigens26,33,58–63, we co-expressed
CSDE1C-T from VSV-IFNβ to prime escape-specific T-cell
responses. VSV-IFNβ-CSDE1C-T replicated significantly less well
than VSV-IFNβ or VSV-IFNβ-CSDE1WT (Figs. 4B and 5G), but
induced potent T-cell responses against the CSDE1P5S EATA
(Fig. 5B), which completely prevented escape (Fig. 5F) in the
presence of anti-PD-1 ICB. Anti-CSDE1P5S T cells still had anti-
tumor efficacy without ICB as evidenced by the significant
reduction in tumor volumes in Fig. 5A. In addition, anti-
CSDE1P5S CD8 T cells had anti-tumor activity against B16
tumors even in the absence of anti-PD-1 ICB (e.g., Supplemen-
tary Fig. 3A) and were active against B16 tumors, which escaped
VSV-IFNβ therapy without anti-PD-1 ICB, at least in the context
of in vivo activation and adoptive T-cell transfer (Supplementary
Fig. 3B). Although VSV-mIFNβ-CSDE1WT was a significantly
better oncolytic than VSV-IFNβ (Figs. 4B, C and 5F, G), it did not
generate α-CSDE1WT or α-CSDE1P5S T-cell responses (Fig. 5B),
suppressed evolution of the CSDE1P5S immunogen in escaping
cells (Fig. 4D), and was not as effective as VSV-IFNβ-CSDE1C-T
(Fig. 5F). Thus, the therapeutic value of T-cell control of emer-
ging escape variants outweighed the loss of oncolytic potency of
VSV-IFNβ-CSDE1C-T (Fig. 5F).
VSV-IFNβ-ESC tumors in vivo rarely contained a completely
homogenous population of CSDE1C-T mutant tumor cells (Sup-
plementary Fig. 1J). Therefore, the heteroclitic anti-CSDE1P5S T-
cell responses11 (Fig. 5B) probably contribute a significant
bystander effect against tumor cells, which do not become
infected, escape direct oncolysis, or innate immune clearance, or
which do not evolve the CSDE1C-T mutation. This model is
supported by the data in Supplementary Fig. 3, in which adoptive
transfer of anti-CSDE1P5S CD8+ T cells improved survival of
mice bearing B16 (CSDE1WT) tumors (Supplementary Fig. 3A) or
cured them when used in combination with either anti-PD-1 ICB
(Supplementary Fig. 3A) or with frontline, CSDE1P5S-inducing
VSV-IFNβ therapy (without ICB) (Supplementary Fig. 3B).
Thus, it may be that intra-tumoral IL-12 (Fig. 5C), which
correlated with anti-CSDE1P5S T-cell responses (Fig. 5B), reflects
T-cell killing of both CSDE1P5S-positive tumor cells and het-
eroclitic T-cell responses against CSDE1WT cells (Fig. 5F). DC-
CSDE1C-T, with intra-tumoral VSV-IFNβ+ αPD-1, was not as
effective as when the neoantigen was expressed from within the
virus (Supplementary Fig. 2C) and was associated with low-
er intra-tumoral IL-12 (Fig. 5C and Supplementary Fig. 2C).
These data are consistent with a model in which intra-tumoral
Fig. 6 Escape from VSV-hIFNβ is immunogenic. A Human CD3+ T cells activated with αCD3 and αCD28 were co-cultured with autologous CD14+
-matured DC and different Hep3B cell lysates on d1, 3, and 5. On d7, CD8+ T cells were isolated and co-cultured with autologous DC and the same Hep3B
cell lysates (E : T 10 : 1). B Seventy-two hours later, supernatants were assayed for IFN-γ. Means ± SD of three technical replicates from three donors. C 104
target cells (Hep3BP or Hep3B-VSV-hIFN-β 21d ESC) were treated for 24 h with hIFN-γ before being co-cultured with 105 T cells primed/expanded on
Hep3BP or Hep3B-VSV-hIFNβ-21d ESC cells as in A. 105 T cells were added after 48 h. At 120 h, surviving adherent cells were counted. D NetMHC4.0 %
rank of the predicted affinity of the unmutated CSDE1WT 9mer, MSFDPNLLH, and its CSDE1C-T-mutated counterpart 9mer, MSFDSNLLH, compared to
400,000 random peptides for HLA subtypes. Strong binders, %rank < 0.5, weak binders, %rank < 2. http://www.cbs.dtu.dk/services/NetMHC/. E Human
CD3+ T cells activated in vitro were co-cultured with autologous DC and Hep3BP or Hep3B-VSV-hIFNβ-ESC lysates, or with DC transfected 48 h
previously with 10 µg pcDNA3.1-CSDE1WT or pcDNA3.1-CSDE1C-T plasmids. Lysates, or DC, were re-added on d5. On d7, isolated CD8+ T cells were co-
cultured with DC/Hep3B cell lysates or with transfected DC (E : T 10 : 1). Seventy-two hours later, supernatants were assayed for IFN-γ. Means ± SD of
three technical replicates from two donors. ND, below limit of detection. F Activated human CD3+ T cells were co-cultured with autologous DC pulsed 48
h previously with 5 µg/ml peptide on d1 and 5. On d7, isolated CD8+ T cells were co-cultured with similarly pulsed DC. Seventy-two hours later,
supernatants were assayed for IFN-γ. Peptide pulsing: Lane 1: SIINFEKL peptide from Ovalbumin; 2: WT CSDE1 9mer MSFDPNLLH; 3: CSDE1 20mer,
MSFDPNLLHNNGHNGYPNGT, which could be processed into 9-11mer with Pro (position 5) in different positions; 4: mutated CSDE1P5S MSFDSNLLH; or 5:
CSDE1P5S 20mer, MSFDSNLLHNNGHNGYPNGT, in which Ser (position 5) could be at different positions. Means ± SD of three technical replicates from
three donors. P-values determined using a one-way (B) or two- way (C, F) ANOVA with a Tukey’s multiple comparisons post test. Statistical testing was
on log-transformed data in C. Statistical significance, p < 0.05, ns > 0.05. Source data are provided as a Source Data file.
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VSV-IFNβ-CSDE1C-T provides both high levels of inflammation
(TNF-α in all VSV-injected tumors; Fig. 5D and Supplementary
Fig. 2D), to enhance trafficking of anti−CSDE1P5S-specific
T cells. Simultaneously, VSV-IFNβ-CSDE1C-T also provides
high concentrations of target antigen (CSDE1P5S) (reflected by
IL-12 only in VSV-IFN-β-CSDE1C-T-injected tumors; Fig. 5C),
which are lacking with intraperitoneal (i.p.) DC and intra-
tumoral VSV-IFNβ.
We targeted the CSDE1P5S mutation in cells, which escaped
VSV-IFNβ therapy, because it was the highest frequency muta-
tion in VSV-IFNβ ESC cells and, therefore, represents a “trunk-
like” mutation in cells escaping VSV-IFNβ (Supplementary
Fig. 1). However, applying intense immunotherapeutic pressure
against the CSDE1P5S mutation, as in Fig. 5, may allow other,
lower frequency (branch-like) escape-induced mutations to
become more prominent in ESC populations, to compensate for a
requirement of ESC tumors to lose detectable expression
of CSDE1P5S completely. These mutations may be in cellular
proteins/pathways affecting, e.g., viral replication, the antiviral
response and/or antigen presentation.
Human VSV-hIFNβ-ESC tumor cells were also significantly
more immunogenic than untreated cells (Fig. 6), implying neo-
antigenesis of EATA. These could include CSDE1P5S, which was
present at high clonality (Supplementary Fig. 1I), knockdown of
which significantly reduced T-cell activation (Fig. 6B). Transla-
tion of virotherapy with escape-targeting immunotherapy will
require identification of HLA-/patient-specific EATA, such as
CSDE1P5S where HLA compatibility is predicted (Fig. 6D), or the
simultaneous targeting of multiple (unidentified) EATA—e.g.,
using VSV-expressed cDNA libraries derived from treatment-
escape tumors58–60.
In summary, we have exploited the inherent genetic plasticity
of tumors by using oncolytic virotherapy to drive them into an
escape phenotype, which can then be ambushed by vaccination
against a predictably arising EATA. This approach is likely to be
widely applicable across a range of different frontline therapies,
which are potent enough to drive tumor cell mutation/evolution,
thereby inducing neo-antigenesis resulting in a novel immuno-
peptidome associated with acquired treatment resistance.
Methods
Experimental design. These experiments were designed to evaluate how repro-
ducible mutations induced in tumor cells escaping oncolytic virotherapy could be
exploited for the design of immunotherapies targeting treatment escape. The
investigators were not blinded to the allocation of groups during experiments or
subsequently during the analysis. Although statistical methods were not used to
predetermine the sample size, sample sizes were chosen on the basis of estimates
from pilot experiments and previously published results. Seven to ten mice per
group were used for each survival experiment to achieve statistical power, to make
multiple comparisons. Animals were randomized to treatment groups following
tumor implantation using the GraphPad QuickCalcs online tool (https://www.
graphpad.com/quickcalcs/randMenu/). The n-values and particular statistical
methods are indicated in the figure legends and the statistical analysis section.
Cell lines and viruses. B16 murine melanoma and human Hep3B hepatocellular
carcinoma and BHK cells were originally obtained from American Type Culture
Collection (ATCC). Human Mel888 melanoma cells were obtained from the
Imperial Cancer Research Fund in 1997/1998 and were grown in Dulbecco’s
modified Eagle medium (DMEM; Hyclone, Logan, UT, USA)+ 10% fetal bovine
serum (FBS) (Life Technologies). Cell lines were authenticated by morphology,
growth characteristics, PCR for tissue-specific gene expression (gp100, TYRP-1,
and TYRP-2) and biologic behavior, tested mycoplasma-free (MycoAlert Myco-
plasma Detection Kit, Lonza), and frozen. Cells were cultured for <3 months after
thawing.
B16TK cells were derived from a B16.F1 clone transfected with a plasmid
expressing the Herpes Simplex Virus thymidine kinase (HSV-1 TK) gene9.
Following stable selection in 1.25 µg/mL puromycin, these cells were shown to be
sensitive to Ganciclovir (Cymevene) at 5 µg/ml. B16TK cells were grown in
DMEM+ 10% FBS (Life Technologies)+ 1.25 µg/mL puromycin (Sigma).
B16-CSDE1WT, B16-CSDE1C-T, Hep3B-CSDE1WT, Hep3B-CSDE1C-T, or
Mel888-CSDE1WT or CSDE1CSDE1C-T cell lines were generated by transfection of
parental B16, Hep3B, or Mel888 cells with pcDNA3.1 expression vectors expressing
either the murine (B16) or human (Hep3B and Mel888) CSDE1 wild-type (non-
mutated) or CSDE1C-T-mutated genes, isolated by PCR from B16 or Hep3B cells
that had escaped in vitro oncolysis by VSV-mIFNβ (B16) or VSV-hIFNβ (Hep3B)
in the 21-day selection protocol10 described below. Forty-eight hours after
transfection, cells were selected in G418 (5 mg/ml B16, 3 mg/ml Hep3B, and 1 mg/
ml Mel888) for 2 weeks. Overexpression of the CSDE1 proteins was confirmed in
these bulk G418r populations of cells by western blotting.
VSV expressing murine IFNβ (VSV-mIFNβ), human IFNβ (VSV-hIFNβ)25,
murine CSDE1WT, murine CSDE1C-T, or green fluorescent protein (VSV-GFP)
was rescued from the pXN2 cDNA plasmid using the established reverse genetics
system in BHK cells as previously described22,25,26,58. In brief, BHK cells are
infected with MVA-T7 at an MOI of 1. Cells are incubated at 37 °C and 5% CO2.
After 1 h, cells are transfected with pVSV-XN2 genomic VSV plasmid (10 μg),
pBluescript (pBS) encoding VSV-N (3 μg), pBS encoding VSV_P (5 μg), and pBS
encoding VSV L proteins (1 μg) using Fugene6 according to the manufacturer’s
recommendations. Cells were incubated at 37 °C and 5% CO2 for 48 h. After 48 h,
supernatant was collected and clarified by passing through a 0.2 μm filter. All
transgenes were inserted between viral G and L genes using the XhoI and NheI
restriction sites. VSV co-expressing murine, or human, IFNβ and CSDE1WT or
CSDE1C-T were also generated by cloning the CSDE1 genes between the viral M
and G genes. Virus titers were determined by plaque assay on BHK cells or on the
stated cell lines in the text.
Mice. Female C57BL/6 mice were obtained from The Jackson Laboratory at
6–8 weeks of age Athymic nude mice Foxn1nu/nu were obtained from Envigo at
4–6 weeks of age. All mice were maintained in a pathogen-free BSL2 biohazard
facility. This facility is maintained between 68 and 79 °F with humidity from 30%
to 70% and on a 12 h light/dark cycle. All animal studies were approved by the
Institutional Animal Care and Use Committee at Mayo Clinic.
In vivo experiments. All in vivo studies were approved by the Institutional Animal
Care and Use Committee at Mayo Clinic. Mice were challenged subcutaneously
with 2 × 105 B16 melanoma cells, in 100 μL PBS (HyClone, Logan, UT, USA).
Subcutaneous tumors were treated with doses of 5 × 107 pfu of VSV delivered i.t. in
50 µL of PBS. Tumors were measured using calipers three times per week and mice
were killed when tumors reached 1.0 cm in diameter. For experiments using ICB,
mice received 300 µg each of anti-mouse PD-1 (clone RMP1-14), per dose i.p.
(BioXCell catalog number BE0146). Control mice received 300 µg of control rat
IgG (Jackson ImmunoResearch catalog number 012-000-003).
Immune cell activation. Spleens and lymph nodes from C57Bl/6 mice were
immediately excised upon killing. Single-cell suspensions were achieved in vitro via
mechanical dissociation. Red blood cells were lysed by resuspension in
ammonium-chloride-potassium (ACK) lysis buffer and incubating at room tem-
perature for 2 min. Cells were resuspended at a concentration of 1 × 106 cells/mL in
Iscove’s modified Dulbecco’s medium (Gibco) supplemented with 5% FBS, 1%
penicillin–streptomycin, and 40 μmol/L 2-Mercaptoethanol. Splenocytes were co-
cultured with target cells at various effector to target ratios or with stimulating
peptides as described in the text. Supernatants from co-cultures were collected and
assayed for TNF-α and IFN-γ by enzyme-linked immunosorbent assay (ELISA) as
per the manufacturer’s instructions (Mouse TNF-α or Mouse IFN-γ ELISA Kit,
OptEIA, BD Biosciences, San Diego, CA).
In vitro selection of virus-resistant populations10. B16, Hep3B, or Mel888 cells
were infected for 1 h with VSV at an MOI of 0.01. Cells were washed with PBS to
remove any excess virus and then incubated for 7 days. Cells were washed every
2 days to remove any dead or floating cells. After 7 days, the cells were collected
and re-plated. These cells were subjected to two repeated rounds of infection and
re-plating as just described. After 21 days, three total rounds of infection, the
remaining virus-escaped cells were collected.
qrtPCR and sequencing. RNA was prepared using the QIAGEN-RNeasy-MiniKit
(Qiagen, Valencia, CA) as per the manufacturer’s instructions. One microgram of
total RNA was reverse-transcribed in a 20 µl volume using oligo-(dT) primers
using the First Strand cDNA Synthesis Kit (Roche, Indianapolis, IN). A cDNA
equivalent of 1 ng RNA was amplified by PCR with gene-specific primers using
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the loading control
(mgapdh sense: 5′-TCATGACCACAGTCCATGCC-3′; mgapdh antisense: 5′-
TCAGCTCTGGGATGACCTTG-3′). qrtPCR was carried out using a Light-
Cycler480 SYBRGreenI Master kit and a LightCycler480 instrument (Roche)
according to the manufacturer’s instructions. The ΔΔCT method was used to
calculate the fold change in the expression level of viral RNA (P, M, IGR-M, L, G,
and L-G) and GAPDH as an endogenous control for all treated samples relative to
an untreated calibrator sample.
The following primers were used: P1: 5′-cctctcacca-3′; P2: 3′-gctctcagtt-5′
(120 bp fragment). M1: 5′-gatctaagtg-3′; M2 3′-catacgaggc-5′ (120 bp fragment).
IGR1: 5′-actatgaaaa-3′; G1: 5′-gatataagtt tcctttatac-3′; G2: 3′-ggttcttttctgtctaaata-5′
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(300 bp fragment). L1: 5′-attcctgaat cccgatgagc-3′; L2: 3′-taaactgcaccacctctgga-5′
(300 bp fragment).
Sequencing of the CSDE1 gene. The CSDE1 gene was sequenced using the primer
5′-TCACGAAGTGCTGCTGAAGT-3′ and aligned with NCBI Reference
Sequence: NM_144901.4.
APOBEC3 knockdown. Four unique 29mer shRNA retroviral constructs (Origene
Technologies, Rockville, MD) were used as a combination to significantly reduce
the expression of murine APOBEC3 in B16 cells compared to a single, scrambled
shRNA encoding retroviral construct10. To achieve optimal knockdown for periods
of more than 2 weeks in culture, each construct was pre-packaged as retroviral
particles in the GP+ E86 ecotropic packaging cell line and was used to infect B16
cells at an MOI of ~10 per retroviral construct. In addition, a single, scrambled
negative control, non-effective shRNA cassette was packaged and used to infect
cells, to generate B16 (scrambled shRNA) cells.
Hep3B cells were infected with a retroviral vector encoding either full-length
functional APOBEC3B or a mutated, non-functional form of APOBEC3B as a
negative control obtained from Reuben Harris (University of Minnesota, MN)9–11.
Infected populations were selected for 7 days in hygromycin to generate Hep3B
(APOBEC3B) or Hep3B (APOBEC3B INACTIVE) cell lines, and were used for
experiments as described.
Protein expression analysis. Cells were lysed in NP40 lysis buffer containing
Pierce Protease inhibitor tablets at a final concentration of 1× (ThermoScientific).
Protein lysates were quantified by bicinchonic acid (BCA) assay according to the
manufacturer’s instructions (Pierce, ThermoScientific). Whole tumor cell lysates,
recovered from mice in vivo, were normalized by protein concentration prior to
ELISA determination of IL-12 and TNF-α (OptE1A, BD Biosciences, San Diego), to
ensure equal amounts of protein were assayed from tumors of different sizes. For
western blot analysis of CSDE1 (89 kDa), 20 µg protein lysate was run on a 4–15%
SDS-polyacrylamide gel electrophoresis (PAGE) gel, transferred to polyvinylidene
difluoride (PVDF) membrane, and blotted with anti-CSDE1, a rabbit polyclonal
antibody (Bethyl Laboratories, Montgomery TX, product number #A303-160A), at
a dilution of 1/500, overnight at 4 °C. Membranes were washed with 0.05% Tween-
20 PBS and then probed with anti-rabbit secondary antibody (1/50,000) in 5%
milk. Membranes were developed with chemiluminescent substrate (Thermo
Fisher Scientific). For western blot analysis of VSV M (29 kDa), 20 µg protein lysate
was run on a 4–15% SDS-PAGE gel, transferred to PVDF membrane, and blotted
with anti-VSV Matrix clone 23H12, a mouse monoclonal antibody (EMDMillipore
Corp, Burlington MA, product number #MABF2347), at a dilution of 1/1000,
overnight at 4 °C. Membranes were washed with 0.05% Tween-20 PBS and then
probed with anti-mouse secondary antibody (1/10,000) in 5% milk. Membranes
were developed with chemiluminescent substrate (Thermo Fisher Scientific).
Defective interfering particle assay10. Hep3BP or Hep3B-CSDE1C-T cells were
infected with VSV-hIFNβ or with VSV-IFNβ-IGR P/MC-U at an MOI of 0.01 and
were incubated for 72 h. Supernatant was collected and either left undiluted or
diluted 1 : 10 or 1 : 100 in serum-free medium. Fresh BHK cells were seeded the day
before in triplicate wells and diluted viral supernatants were allowed to adsorb for
1 h. Stock VSV-hIFNβ virus was then added at an MOI of 20 and was incubated for
1 h. Cells were then washed 3× in PBS and fresh supernatant was added. Super-
natant was collected 24 h after infection and was titered by plaque assay, by limiting
the dilution on BHK cells.
Human T-cell in vitro education and re-stimulation. Peripheral blood mono-
nuclear cells were isolated from healthy donor apheresis cones obtained through
the Mayo Clinic Blood Donor Center (approved by the Division of Transfusion
Medicine Research Committee at Mayo Clinic and determined to be institutional
review board exempt). Informed consent was obtained from all donors for the use
of their sample for research purposes. CD3+ T cells were isolated using a magnetic
sorting kit (Miltenyi Biotech) and were activated using CD3/CD28 beads (Thermo
Fisher). T cells were co-cultured at a ratio of 10 : 1 with CD14+ in vitro-matured
dendritic cells prepared from the same donor pre-loaded with lysates from target
tumor cells at a ratio of 1 : 10 Target cell lysate : DC. On days 3 and 5, tumor cell
lysates were re-added to the co-culture. After 7 days of co-culture, CD3+ T cells
were re-isolated using a magnetic sorting kit (Miltenyi Biotech), co-cultured with
newly matured monocyte-derived dendritic cells (MoDCs), and loaded with tumor
cell lysate at a ratio of 1 : 10 Target cell lysate : DC. Three days later, supernatant
was collected for IFN-γ ELISA (R&D).
In separate experiments, CD3+ T cells from donor 3 were treated as above for
7 days and were re-isolated by magnetic sorting. Target tumor cells (104; Hep3B
parental or Hep3B-VSV-hIFNβ 21d ESC) were treated for 24 h with hIFN-γ (200
U/mL for 12 h) and then co-cultured with 105 of the previously primed T cells
(primed/expanded on either Hep3B parental or Hep3B-VSV-hIFNβ 21d ESC cells)
(triplicate wells per treatment). A further 105 T cells were added after 48 h. At 120 h
post co-culture, wells were washed 3× with PBS and the surviving adherent cells
were counted.
Autologous MoDCs were isolated using CD14+ magnetic sorting (Miltenyi
Biotech). Isolated MoDCs were incubated with human granulocyte-macrophage
colony-stimulating factor (GM-CSF; 800 U/mL) and IL-4 (1000 U/mL) to induce
maturation. On Days 3 and 5, media was replaced with fresh human GM-CSF
(1600 U/mL) and IL-4 (1000 U/mL). On Day 7, non-adherent cells were collected,
washed with PBS, and resuspended in medium containing GM-CSF (800 U/mL),
IL-4 (1000 U/mL), TNF-α (1100 U/mL), IL-1β (1870 U/mL), IL-6 (1000 U/mL),
and PGE2 (1 μg/mL), and were incubated for 2 days. Two days later, dendritic cells
were collected for co-incubation with freshly isolated, or pre-activated, T cells at a
ratio of 1 : 10 as described above.
siRNA knockdown of CSDE1. Target cells were transfected with no siRNA, 600
pmol of Silence select Negative siRNA, or with 600 pmol of [s15373+
15374 siRNA] (2 CSDE1-specific siRNA)46 and levels of CSDE1 assayed by western
blotting 24 or 48 h later.
Statistical analyses. All analysis was performed within GraphPad Prism software
(Graphpad). Multiple comparisons were analyzed using one-way or two-way
analysis of variances with a Tukey’s post hoc multi-comparisons test. Survival data
were assessed using the log-rank test using a Bonferroni correction for multiple
comparisons. Data are expressed as group mean ± SD.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data associated with this study are available within the Article, Supplementary
Information, or available from the corresponding authors upon reasonable
request. Source data are provided with this paper.
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